What is TuHURA Biosciences's earnings per share (EPS)?

TuHURA Biosciences (HURA) reported diluted earnings per share of -$0.63 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

TuHURA Biosciences Financials

HURA

FY2025 annual

Revenue $0 YoY not available

Net Income -$31.0M -34.8% YoY

EPS (Diluted) -$0.63 YoY not available

Free Cash Flow -$27.7M -87.4% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

TuHURA Biosciences (HURA) reported $0 in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI HURA FY2025 2026-08-14

TuHURA is operating as a cash-funded development company, where R&D expansion repeatedly pulls the business back to external financing.

In FY2025, financing inflows of $19.9M still left year-end cash at only $3.6M. That gap shows new capital is funding ongoing operating use rather than durable asset buildout, because cash consumed by operations widened from FY2024 to FY2025 while capital spending stayed minimal, so each financing round is largely refilling operating runway.

The cost structure is still research-led: FY2025 R&D reached $20.5M versus SG&A of $7.6M, so the loss base is being driven more by program development than by a scaled commercial organization. The operating model remains science-intensive, so periodic losses say more about the pace of investment than about a business failing to convert sales into cash.

The balance sheet is less liquid than total assets suggest. FY2025 carried $10.7M of goodwill inside $27.4M of assets, while the current ratio fell below 1.0x, meaning headline asset growth did not translate into near-term funding flexibility. That leaves the company looking better capitalized on paper than its immediate spending cushion implies.

Financial Health Signals

Financial health score not available

TuHURA Biosciences does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

2/7

TuHURA Biosciences passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

TuHURA Biosciences reported a net loss of $31.0M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

TuHURA Biosciences generated $0 in revenue in fiscal year 2025.

Net Income

-$31.0M

YoY-34.8%

TuHURA Biosciences reported -$31.0M in net income in fiscal year 2025. This represents a decrease of 34.8% from the prior year.

EPS (Diluted)

-$0.63

TuHURA Biosciences earned -$0.63 per diluted share (EPS) in fiscal year 2025.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$27.7M

YoY-87.4%

TuHURA Biosciences recorded an outflow of $27.7M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 87.4% from the prior year.

Cash & Debt

$3.6M

YoY-71.4%

5Y CAGR+8.6%

10Y CAGR+7.5%

TuHURA Biosciences held $3.6M in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

59M

TuHURA Biosciences had 59M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-148.1%

YoY+9.5pp

TuHURA Biosciences's ROE was -148.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 9.5 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$20.5M

YoY+54.0%

5Y CAGR+41.4%

10Y CAGR+23.2%

TuHURA Biosciences invested $20.5M in research and development in fiscal year 2025. This represents an increase of 54.0% from the prior year.

Capital Expenditures

$76K

YoY+31.4%

TuHURA Biosciences invested $76K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 31.4% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

HURA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

HURA annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0	$0
R&D Expenses	N/A	$20.5M+54.0%	$13.3M+41.8%	$9.4M-38.0%	$15.2M+28.4%	$11.8M+225.5%	$3.6M-0.9%	$3.7M-48.7%	-$7.1M+42.6%	$5.0M+48.9%	$3.4M+31.5%	$2.6M+20.6%	-$2.1M-9.5%	$2.3M	N/A	N/A
SG&A Expenses	N/A	$7.6M+95.8%	$3.9M-6.5%	$4.1M-44.8%	$7.5M-23.0%	$9.8M+116.1%	$4.5M-4.7%	$4.7M+217.2%	-$4.0M-221.8%	$3.3M+16.3%	$2.9M+31.5%	$2.2M+169.2%	-$3.1M-179.3%	$4.0M	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$33K
Interest Expense	N/A	$625K-84.9%	$4.1M+22044.2%	$19K	N/A	$30K	N/A	N/A	N/A	N/A	N/A	$2K+125.7%	-$8K-201.5%	$8K+6.6%	$8K-65.7%	$22K
Income Tax	N/A	$2K-57.5%	$4K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$31.0M-34.8%	-$23.0M-53.3%	-$15.0M+33.8%	-$22.7M+40.8%	-$38.3M-319.7%	-$9.1M-13.4%	-$8.0M-172.3%	$11.1M+237.8%	-$8.1M-191.2%	$8.9M+303.9%	-$4.3M-168.4%	$6.4M+176.7%	-$8.3M	N/A	N/A
EPS (Diluted)	—	-$0.63	-$1.21	-$2.47	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.11	$0.00	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	$0	N/A	N/A	N/A	$0	N/A	N/A
R&D Expenses	$6.6M+26.5%	$5.2M	N/A	$5.0M+0.8%	$4.9M+7.5%	$4.6M	N/A	$2.9M
SG&A Expenses	$2.1M-6.7%	$2.3M	N/A	$1.8M-5.4%	$1.9M-7.7%	$2.0M	N/A	$783K
Interest Expense	$468K+1571.7%	$28K	N/A	$17K	$0	N/A	N/A	$2.0M
Net Income	-$9.2M-22.4%	-$7.5M	N/A	-$7.1M+25.4%	-$9.5M-42.9%	-$6.7M	N/A	-$5.6M
EPS (Diluted)	-$0.14-7.7%	-$0.13	N/A	-$0.14+33.3%	-$0.21-40.0%	-$0.15	N/A	-$0.54

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

HURA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

HURA annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$27.4M+37.0%	$20.0M+357.8%	$4.4M-72.6%	$15.9M+17.8%	$13.5M+361.0%	$2.9M-27.2%	$4.0M-42.9%	$7.1M-10.6%	$7.9M+24.5%	$6.4M+146.8%	$2.6M-48.5%	$5.0M+15.9%	$4.3M+240632.9%	$2K-83.2%	$11K
Current Assets	$4.6M-76.4%	$19.6M+371.5%	$4.2M-68.6%	$13.3M+12.4%	$11.8M+313.6%	$2.9M-29.2%	$4.0M-42.9%	$7.0M-10.5%	$7.9M+24.5%	$6.3M+145.4%	$2.6M-48.5%	$5.0M	N/A	N/A	N/A
Cash & Equivalents	$3.6M-71.4%	$12.7M+245.3%	$3.7M-68.9%	$11.8M+11.8%	$10.5M+340.5%	$2.4M-35.7%	$3.7M-37.7%	$6.0M-9.3%	$6.6M+7.0%	$6.2M+251.0%	$1.8M-63.1%	$4.8M+15.1%	$4.1M	N/A	$6K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$250K	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0-100.0%	$5K
Goodwill	$10.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.4M+19.5%	$5.4M-9.3%	$5.9M+42.6%	$4.2M+40.2%	$3.0M+10.7%	$2.7M+29.2%	$2.1M+26.2%	$1.6M+23.0%	$1.3M-11.0%	$1.5M-55.9%	$3.4M-42.5%	$5.9M+15.0%	$5.1M+51349.6%	$10K	$0
Current Liabilities	$5.9M+11.1%	$5.3M+48.2%	$3.6M-9.9%	$4.0M+43.5%	$2.8M+3.9%	$2.7M+29.2%	$2.1M+26.3%	$1.6M+25.6%	$1.3M+107.9%	$627K-26.4%	$853K+184.5%	$300K+20.2%	$249K	N/A	$0
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1K-96.0%	$28K-95.9%	$694K-31.8%	$1.0M	N/A	N/A	N/A	N/A
Total Equity	$20.9M+43.4%	$14.6M+1036.3%	-$1.6M-113.2%	$11.8M+11.5%	$10.6M+3923.2%	$263K-86.6%	$2.0M-63.8%	$5.4M-17.4%	$6.6M+35.4%	$4.9M+691.5%	-$821K+8.8%	-$901K-10.2%	-$818K-9887.5%	-$8K-176.6%	$11K
Retained Earnings	-$141.2M-27.1%	-$111.1M-25.6%	-$88.5M+35.1%	-$136.4M-22.6%	-$111.2M-59.5%	-$69.7M-15.1%	-$60.6M-15.5%	-$52.4M-27.5%	-$41.1M-27.5%	-$32.2M-73.2%	-$18.6M-30.5%	-$14.3M	N/A	N/A	-$39K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$31.7M+6.9%	$29.7M+8.6%	$27.4M+6.4%	$25.7M-25.8%	$34.6M+136.5%	$14.6M-26.7%	$20.0M+382.3%	$4.1M
Current Assets	$1.7M-76.3%	$7.0M+51.1%	$4.6M+31.9%	$3.5M-72.1%	$12.5M-12.5%	$14.3M-27.0%	$19.6M+463.0%	$3.5M
Cash & Equivalents	$996K-84.2%	$6.3M+74.0%	$3.6M+34.2%	$2.7M-68.3%	$8.5M+36.9%	$6.2M-50.9%	$12.7M+319.1%	$3.0M
Goodwill	$10.7M0.0%	$10.7M0.0%	$10.7M-20.8%	$13.6M0.0%	$13.6M	N/A	N/A	N/A
Total Liabilities	$13.2M+103.3%	$6.5M+1.5%	$6.4M-28.0%	$8.9M-41.2%	$15.2M+217.3%	$4.8M-11.0%	$5.4M-22.2%	$6.9M
Current Liabilities	$9.3M+52.5%	$6.1M+2.5%	$5.9M-33.0%	$8.8M-41.8%	$15.2M+217.3%	$4.8M-10.3%	$5.3M+136.2%	$2.3M
Long-Term Debt	$3.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$18.5M-20.2%	$23.2M+10.8%	$20.9M+24.8%	$16.8M-13.7%	$19.4M+97.3%	$9.9M-32.5%	$14.6M+627.4%	-$2.8M
Retained Earnings	-$157.9M-6.2%	-$148.7M-5.3%	-$141.2M-5.0%	-$134.4M-5.6%	-$127.3M-8.1%	-$117.8M-6.0%	-$111.1M+31.4%	-$162.1M

HURA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

HURA annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$29.7M	-$27.6M-87.6%	-$14.7M-23.2%	-$12.0M+41.4%	-$20.4M-8.1%	-$18.9M-137.9%	-$7.9M-25.3%	-$6.3M+35.8%	-$9.9M-22.8%	-$8.0M-55.8%	-$5.1M-33.6%	-$3.9M+3.8%	-$4.0M+27.5%	-$5.5M	N/A	-$39K
Capital Expenditures	$214K	$76K+31.4%	$58K-26.9%	$79K-56.0%	$180K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$29.9M	-$27.7M-87.4%	-$14.8M-22.9%	-$12.0M+41.5%	-$20.6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$214K	-$1.3M+77.9%	-$6.1M-366.7%	-$1.3M	N/A	$964K	N/A	N/A	-$13K+39.6%	-$21K-25.0%	-$17K	N/A	N/A	N/A	$0	$0
Financing Cash Flow	$22.4M	$19.9M-33.1%	$29.8M+1019.2%	$2.7M-87.7%	$21.6M-16.9%	$26.0M+294.5%	$6.6M+62.0%	$4.1M-56.0%	$9.2M+9.2%	$8.5M-11.5%	$9.6M+1028.3%	$848K-65.8%	$2.5M	N/A	$7K	$0
Share Buybacks	N/A	N/A	N/A	$25K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$8.6M-95.6%	-$4.4M+20.6%	-$5.6M+49.9%	-$11.1M-77.4%	-$6.2M-31.9%	-$4.7M-82.3%	-$2.6M-37.6%	-$1.9M
Capital Expenditures	$137K+180.4%	$49K+75.4%	$28K	$0-100.0%	$6K-87.0%	$43K+99.3%	$21K	$0
Free Cash Flow	-$8.8M-96.6%	-$4.5M+20.1%	-$5.6M+49.6%	-$11.1M-77.3%	-$6.3M-30.8%	-$4.8M-82.4%	-$2.6M-38.8%	-$1.9M
Investing Cash Flow	-$137K-180.4%	-$49K-75.4%	-$28K	$0+100.0%	-$156K+86.4%	-$1.2M-39.8%	-$824K+84.1%	-$5.2M
Financing Cash Flow	$3.5M-51.4%	$7.1M+9.7%	$6.5M+23.4%	$5.3M-39.4%	$8.7M+1687.5%	-$548K+84.4%	-$3.5M-122.4%	$15.7M

Not reported in any period shown, so not listed: Dividends Paid.

HURA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

HURA annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Return on Equity	-148.1%+9.5pp	-157.6%	N/A	-192.1%+169.8pp	-361.9%+3108.0pp	-3470.0%-3061.0pp	-408.9%-613.9pp	204.9%+327.8pp	-122.8%-305.3pp	182.4%	N/A	N/A	N/A	N/A	N/A
Return on Assets	-113.3%+1.9pp	-115.2%+228.7pp	-343.9%-201.8pp	-142.1%+140.7pp	-282.8%+27.8pp	-310.6%-111.3pp	-199.3%-356.8pp	157.4%+259.6pp	-102.2%-241.6pp	139.5%+308.3pp	-168.8%-295.9pp	127.1%+319.0pp	-192.0%	N/A	N/A
Current Ratio	0.78-2.9x	3.68+2.5x	1.16-2.2x	3.32-0.9x	4.24+3.2x	1.07-0.9x	1.94-2.4x	4.30-1.7x	6.03-4.0x	10.07+7.1x	3.02-13.7x	16.69	N/A	N/A	N/A
Debt-to-Equity	0.31-0.1x	0.37	N/A	0.35+0.1x	0.28-9.9x	10.17+9.1x	1.05+1.1x	0.000.0x	0.00-0.1x	0.14	N/A	N/A	N/A	N/A	0.00

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Return on Equity	-49.9%-17.3pp	-32.5%	N/A	-42.3%+6.6pp	-49.0%+18.6pp	-67.6%	N/A	N/A
Return on Assets	-29.0%-3.7pp	-25.4%	N/A	-27.6%-0.1pp	-27.5%+18.0pp	-45.5%	N/A	-134.8%
Current Ratio	0.18-1.0x	1.15+0.4x	0.78+0.4x	0.40-0.4x	0.83-2.2x	3.00-0.7x	3.68+2.1x	1.54
Debt-to-Equity	0.19-0.1x	0.280.0x	0.31-0.2x	0.53-0.2x	0.78+0.3x	0.49+0.1x	0.37	N/A

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Note: The current ratio is below 1.0 (0.78), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Io Biotech, Inc. IOBT

$3.5M

Oncolytics Biotech Inc ONCY

$106.0M

Pyxis Oncology, Inc. PYXS

$281.1M

Avalo Therapeutics Inc AVTX

$1.1B

Skye Bioscience SKYE

$10.8M

Where TuHURA Biosciences Ranks

Frequently Asked Questions

What is TuHURA Biosciences's annual revenue?

TuHURA Biosciences (HURA) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is TuHURA Biosciences profitable?

No, TuHURA Biosciences (HURA) reported a net income of -$31.0M in fiscal year 2025.

What is TuHURA Biosciences's return on equity (ROE)?

TuHURA Biosciences (HURA) has a return on equity of -148.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is TuHURA Biosciences's free cash flow?

TuHURA Biosciences (HURA) recorded an outflow of $27.7M in free cash flow during fiscal year 2025. This represents a -87.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is TuHURA Biosciences's operating cash flow?

TuHURA Biosciences (HURA) recorded an outflow of $27.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are TuHURA Biosciences's total assets?

TuHURA Biosciences (HURA) had $27.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are TuHURA Biosciences's capital expenditures?

TuHURA Biosciences (HURA) invested $76K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does TuHURA Biosciences spend on research and development?

TuHURA Biosciences (HURA) invested $20.5M in research and development during fiscal year 2025.

How many shares does TuHURA Biosciences have outstanding?

TuHURA Biosciences (HURA) had 59M shares outstanding as of fiscal year 2025.

What is TuHURA Biosciences's current ratio?

TuHURA Biosciences (HURA) had a current ratio of 0.78 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is TuHURA Biosciences's debt-to-equity ratio?

TuHURA Biosciences (HURA) had a debt-to-equity ratio of 0.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is TuHURA Biosciences's return on assets (ROA)?

TuHURA Biosciences (HURA) had a return on assets of -113.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is TuHURA Biosciences's cash runway?

Based on fiscal year 2025 data, TuHURA Biosciences (HURA) had $3.6M in cash against an annual operating cash burn of $27.6M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is TuHURA Biosciences's Piotroski F-Score?

TuHURA Biosciences (HURA) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are TuHURA Biosciences's earnings high quality?

TuHURA Biosciences (HURA) reported a net loss of $31.0M while operations used $27.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.